𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Langerhans cell histiocytosis in children under 2 years of age

✍ Scribed by Rivera-Luna, Roberto; Alter-Molchadsky, Nejemie; Cardenas-Cardos, Rocío; Martínez-Guerra, Guillermo


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
723 KB
Volume
26
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis


This is a retrospective study of 55 children under the age of 2 years diagnosed with Langerhans cell histiocytosis (LCH). They were classified according to age and organ function and dysfunction following Lahey's criteria. The studied population was divided into four groups by age of diagnosis (0-6, 7-12,13-18, and 19-24 months). Statistical analysis showed no significant difference in outcome between age groups, although the population under 6 months had a 81.3% fatality rate. The presence of organ dysfunction was a major cause of death in all age groups, being statistically significant in outcome ( P > 0.005) compared with patients without organ dysfunction. The presence of thrombocytopenia andlor respiratory dysfunction was also highly associated with a fatal outcome. In the surviving population, no second malignancies have been reported. The late secondary effects of therapy include endocrine, orofacial, and osseous pathologies. 0 1996Wiley-Liss, Inc.


📜 SIMILAR VOLUMES


Histiocytosis syndromes in children: II.
✍ Broadbent, Valerie ;Gadner, Helmut ;Komp, Diane M. ;Ladisch, Stephan 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB

Langerhans cell histiocytosis (LCH) has Society. Adoption of a uniform clinical/labopresented problems in diagnosis and in ratory approach to these children, coupled treatment.Thedefinitivediagnosis isapatho-with agreed-upon steps to the pathologic logic one. To advance thorough and uni-identificati

“Etoposide in the treatment of six child
✍ Whitlock, James A. 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

Viana et al. [I] described their experience with etoposide (VP-16) as initial therapy in the management of patients with Langerhans cell histiocytosis (LCH). However, caution should be used in advocating the use of an epipodophyllotoxin as the "drug of choice" for the treatment of this disorder. Alt

Langerhans cell histiocytosis in childre
✍ Schultz, Christian; Klouche, Mariam; Friedrichsdorf, Stefan; Richter, Nina; Kroe 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

Background. Langerhans cell histiocytosis (LCH) is characterized by monoclonal proliferation of activated Langerhans cells. Neither etiology nor pathomechanism of this disorder is presently known. However, despite monoclonality LCH might represent a reactive clonal disorder induced by immune dysfunc